Free Trial

Johnson & Johnson (JNJ: Aaa/ AAA neg): 2Q24 Results

HEALTHCARE
  • Mixed:
  • Company cuts guidance FY for EPS by 5.5%
  • BUT Company beats estimates for 2Q24 for EPS by 4.23%
  • Revenue $22,447m beat estimates by 0.58%
  • Stelara accounts for 12.8% of Revenue - this will erode soon.
  • No significant update on Litigation
  • Company is upbeat on new pipeline drugs - Tremfya & Rybrevant - as well as integration on Shockwave. And yet, are guiding lower for Full Year.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.